Following the FDA’s approval of Auvelity for treating agitation associated with Alzheimer’s disease (ADA), Axsome Therapeutics has significantly increased its peak sales guidance for the drug to $8 billion.
The impact of expanded indication Previously, Auvelity was projected to reach peak sales between $2.5 billion and $6 billion. However, becoming the first non-antipsychotic medication approved for Alzheimer’s agitation has reshaped company expectations:
-
Revenue split: Axsome anticipates a 50-50 revenue distribution between its two primary indications: Major Depressive Disorder (MDD) and Alzheimer’s Disease Agitation (ADA).
-
Competitive advantage: While Rexulti remains a competitor, Auvelity holds a distinct advantage as it does not carry the “black box warning” regarding increased mortality risk in elderly patients with dementia, which is common in antipsychotics.
-
Market potential: With approximately 76% of the 7 million Alzheimer’s patients in the U.S. suffering from agitation, the drug addresses a massive underserved market.
Market and analyst reactions The announcement triggered a 23% surge in Axsome’s share price within days. Nevertheless, financial analysts remain somewhat skeptical:
-
Mizuho Securities: Increased its projection from $3.2 billion to $5 billion, still notably lower than the company’s $8 billion target, citing skepticism regarding such an ambitious figure.
-
Expansion strategy: Axsome is expanding its sales force to 630 representatives, targeting 68,000 healthcare professionals in preparation for the ADA indication launch next month.
Future outlook Beyond the current indications, Axsome is investigating Auvelity for smoking cessation and other central nervous system disorders, utilizing its unique mechanism targeting NMDA and sigma-1 receptors. Analysts also suggest that the bold guidance might serve as a subtle signal regarding Axsome’s potential interest in future M&A activities.